This study demonstrated the real‐world data about the combination of an EGFR TKI and an anti‐VEGF agent as the first‐line therapy for stage IV lung adenocarcinoma harboring susceptible EGFR mutation in Taiwan. Here, VEGFA is linked to lung adenocarcinoma.